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Background: Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a rare tumor predisposition syndrome
characterized by cutaneous and uterine leiomyomas and papillary type 2 renal cell cancer. Germline mutation of
the fumarate hydratase (FH) gene is known to be associated with HLRCC.
Case presentation: We describe a 64-year-old father and his 39-year-old son with HLRCC who developed papillary
type 2 RCCs lacking cutaneous leiomyomas at any site. A common missense mutation in the FH gene, (c.1021G > A,
p.D341N) in exon 7, was detected in the 2 cases. Functional prediction with the bioinformatics programs, SIFT and
Polyphen-2, reported “damaging (SIFT score 0.00)” and “probably damaging (PSIC score 1.621)” values, respectively.
In 162 healthy individuals, there were no cases of a G transition to any base. Finally, (c.1021G > A) in exon 7, was
identified as a point mutation.
Conclusion: We report a family with HLRCC in which a novel missense mutation was detected. A familial papillary
type 2 renal cancer should be considered HLRCC unless typical cutaneous leiomyomas do not occur.
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Hereditary leiomyomatosis and renal cell cancer (HLRCC:
OMIM 605839) is an inherited autosomal dominant
cancer syndrome characterized by cutaneous leiomyoma,
uterine leiomyoma, and/or a single renal tumor [1]. Cuta-
neous leiomyomas are the commonest clinical feature,
arising in over 80% of HLRCC patients, and RCC is found
in 20-35% of them with an early onset often at 30-50 years
of age [2]. The renal cell cancers in this syndrome are
mostly papillary type 2 RCC, which are often solitary and
unilateral, and they are more likely to be aggressive.
HLRCC is caused by heterozygous germline mutations in
the fumarate hydratase (FH) gene, which is located at
1q42.3-43 [3]. The FH gene codes for fumarate hydratase,
which is an enzyme that catalyzes the conversion of* Correspondence: yychihara@gmail.com
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unless otherwise stated.fumarate to malate in the Krebs cycle. Mutations of the
FH gene, including missense, frameshift, and complete or
partial deletions, have been detected in 90% of HLRCC
families, suggesting that the FH gene has the characteris-
tics of a tumor suppressor gene. HLRCC is comparatively
rare, and so far, 180 HLRCC families have been identified
worldwide [4]. The FH mutation database provides a total
of 155 variants, as of the last up-date on August 17, 2011
[5]. Here, we present a HLRCC family with arising pa-
pillary type 2 RCCs, in which a novel missense germline
mutation in the FH gene was detected.Case presentation
Case 1
A 64-year-old man had anorexia and body weight loss of
10 kg for 3 months before referral. Contrast enhanced
computed tomography (CECT) revealed a huge mass
arising on his left kidney (Figure 1), and swelling in his
pulmonary and para-aorta lymph nodes. On admission,
Karnofsky performance status was 80, blood chemicall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 CT imaging and pathology of renal cancers arising in a family with HLRCC. Case 1: A large renal cell cancer of the left kidney and
para-aortic lymph node swelling (arrow). Case 2: Right renal mass appearing predominantly less enhanced compared with the normal renal
parenchyma (arrow). Pathological findings of both cases showed papillary architectures, large cells, spherical nuclei, and varying degrees of nuclear
pseudostratification. The cytoplasm was voluminous and eosinophilic. (H&E, × 400).
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dehydrogenase (LDH): 239 IU/L, Corrected serum calcium
(Ca): 9.1 mg/dL. This case was categorized into poor risk
according to MSKCC (Memorial Sloan-Kettering Cancer
Center) criteria [6]. Cytoreductive nephrectomy was
performed in September 2007, and a pathological diag-
nosis indicated papillary renal cell carcinoma type 2
with adjacent lymph-node involvement (pT4N2M1).
The patient developed systemic lymph node and bone
metastasis after surgery. Although he was treated with
interferon-α, interleukin-2, sunitinib, and palliative
radiation therapy, he died 17 months after surgery.
Case 2
A 39-year-old man, who was the eldest son of the pa-
tient in Case 1, did not have any symptoms but asked
for extensive testing. CECT revealed a right renal tumor
3 cm in diameter (Figure 1). Laparoscopic radical neph-
rectomy was performed in November 2008, and the
tumor was determined to be pathological papillary renal
cell carcinoma type 2 (pT1aN0M0). Systemic lymph
node and lung metastasis arose 11 months after neph-
rectomy. At that point, the cases show no abnormal
hematological findings, was categorized into favourable
risk according to MSKCC criteria. He was treated with
interferon-α kept stable disease for 12 months. However,
metastasis also arose in the fourth lumbar vertebra at
23 months after nephrectomy. He was treated with tem-
sirolimus. Finally, he died 50 months after surgery.
Written informed consent was obtained from both pa-
tients before their deaths, for germline mutation analysisof the von Hippel-Lindau (VHL) and FH gene, and the
study was approved by the Medical Ethic Committee of
Nara Prefectural Nara Hospital. DNA was extracted
from their peripheral blood leukocytes (PBLs), and was
directly sequenced to include all coding exons of VHL
and FH as described previously [7,8]. No mutation was
detected in VHL. However, the analysis revealed a single
missense mutation (c.1021G > A, p.D341N) in exon 7 of
FH, which was common to both cases (Figure 2). This
missense mutation has not been reported.
Genetic findings
In silico, SIFT (Sorting Intolerant from Tolerant [9])
analysis provided a SIFT score of (p.D341N) for “0.00”.
This score indicates that the mutations is “damaging”.
Similarly, Polyphen-2 (Polymorphism Phenotyping-2
[10]) provided a PSIC score of “1.621”, which indicates
that the mutation is “possibly damaging”. We performed
genotyping analysis of the missense mutation using 162
healthy blood samples. Because (c.1021G > A) is a novel
FH mutation, we should exclude the possibility that this
mutation might be a novel single nucleotide polymorph-
ism (SNP), which is defined as a minor allelic frequency of
more than 1%. Both the HLRCC cases showed (c.1021G >
A). There was no case of a G transition to any base among
162 healthy individuals (Figure 3). Finally, (c.1021G >A)
in exon 7 was identified as a point mutation.
Conclusion
Hereditary renal cell cancer comprises an estimated 3-
5% of RCCs, and to date, 10 HRC syndromes have been
Figure 2 Partial sequence of the FH gene in exon 7. Heterozygous mutations (c.1021G > A) were found in both Case 1 and 2.
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accounting for 70-80% of all RCCs, and VHL inactivation
is very common in both sporadic clear cell RCC and the
hereditary cancer syndrome known as von Hippel-Lindau
disease [12]. Papillary RCC accounts for 10-15% of all
RCCs. Papillary RCCs are divided into type 1 and type 2,
with the object of histopathological findings. The MET
gene mutation occurs in both hereditary and sporadic
papillary type 1 RCCs, whereas the FH gene mutation
is detected only in hereditary papillary type 2 RCC as a
germline mutation [8].
The FH gene encodes fumarate hydratase, which is an
enzyme of the Krebs cycle that catalyzes the conversion
of fumarate to malate. Thus, FH deficiencies are thought
to result in chronic accumulation of fumarate, and leadFigure 3 Pyrograms of genotyping analysis. The peak at the fifth base p
“A” increased, relatively. Wild type showed the same peak between G and
in this position, which was G in the wild type.to competitive inhibition of hypoxia induced factor (HIF)
prolyl hydroxylase (HPH). Under normoxic conditions,
hydroxylated HIF is recognized by the VHL complex and
targeted for ubiqutin-mediated degradation. When HPH
is inhibited, HIF remains unhydroxylated and avoids
degradation. Then, accumulated HIF consequently upre-
gulates HIF target genes such as VEGF, GLUT1, PDGF,
and TGFα, which facilitate tumor growth [13]. Thus, the
molecular pathway for tumor growth in FH deficiencies
closely resembles VHL deficiency in clear RCCs. However,
no association has been verified between the renal cancer
phenotype and the type or location of the FH mutation or
FH enzyme activity [14]. Indeed, to address the FH defi-
ciencies in the tumor tissues, we performed immunohisto-
chemistry of FH and HIF1. We did not find any differenceosition, “G” in the HLRCC cases, decreased. Subsequently the peak of
A. This genotyping revealed that the HLRCC cases’ genotypes were G/A
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clear RCC or normal kidney tissues (data not shown).
The most common type of FH mutation is missense
(57%), followed by frameshift and nonsense (27%), and
diverse deletions, splice site and duplications [15]. A total
of 73 missense mutations have been reported, spanning
exons 2 to 10. Mutations in exon 7 are the most common,
and account for 23 of the total reported mutations. Our
cases showed a common missense mutation (c.1021G > A,
p.D341N), and the same substitution (c.1021G > T, p.
D341Y) was also reported [16]. From the genotyping
results, these substitutions were defined as missense
mutations. Several missense mutations around (c.1021G)
were reported i.e. (c.1002 T >G), (c.1004 T > C), and
(c.1020 T >A). These loci might be a hot spot for FH
mutations. A very small number of these mutations have
known changes in FH enzymatic activity, although most
of them have SIFT scores of “0.00”.
HLRCC-associated renal cancers are early onset and
very aggressive, and most reported patients died within
5 years of diagnosis [17]. Radical surgery may be beneficial
in the early stages, although the optimal management for
HLRCC has not been established. A potential promising
results for locally advanced and metastatic papillary RCC
have been reported with mammalian target of rapamycin
(mTOR) inhibitors, temsirolimus. Exploratory subgroup
analysis of 3-arm phase III trial comparing temsirolimus,
interferon-α or both including 55 papillary RCCs revealed
that temsirolimus group had prolonged overall survival
and progression-free survival compared to patients treated
with interferon-α [18]. Another potential agent might be
erlotinib, an oral epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor. A multicenter phase IItrial of
erlotinib in patients with locally advanced and metastatic
papillary RCCs revealed an overall response rate of 11%
with an additional 53% experiencing stable disease [19].
Unfortunately these data are not specific for HLRCC. A
crinical trial evaluating the combined effect of bevacizu-
mab and erlotinib in patients with advanced HLRCC is
currently under way [20].
Smit et al. [21] advocated the proposed criteria for the
clinical diagnosis of HLRCC as follows. Major criterion:
multiple cutaneous pioleiomyomas confirmed histopatho-
logically. Minor criteria: 1) surgical treatment for severely
symptomatic uterine leiomyomas before age 40, 2) type 2
papillary renal cell carcinoma before age 40, and 3) a first-
degree family member who meets one of the above-
mentioned criteria. The diagnosis is likely when a proband
meets the major criterion, and HLRCC may be suspected
when a proband meets at least 2 minor criteria. However,
in our cases, no cutaneous leiomyomas were found, but
the first-degree family developed early onset papillary type
2 RCC with the same pathological features as the father,
and this should be primarily considered as HLRCC.To our best knowledge, a novel missense mutation of
the FH gene was confirmed by genotyping and in silico
analysis. Papillary type 2 RCCs, which have a familial oc-
currence, should be used for HLRCC identification, if no
cutaneous leiomyomas develop. When a germline muta-
tion is identified, all family members should be offered
appropriate counseling and genetic testing.Material and methods
DNA extraction
Peripheral blood leukocytes (PBLs) from 162 healthy co-
horts were used for consecutive genetic analysis. These
samples were collected by following protocols that were
approved by the Medical Ethics Committee of Nara
Medical University. Written informed consent was ob-
tained from all participants. DNA was extracted according
to standard procedures.
Functional prediction of FH mutation in silico
The impact of the (p.D341N) missense mutation on pro-
tein function was assessed with SIFT and PolyPhen-2.
Both SIFT and PolyPhen-2 are online prediction tools that
predict the degree of impact of an amino acid substitution
on the structure and function of a human protein. SIFT
provides a SIFT Score in which a value of less than 0.05
indicates that the amino acid substitution is predicted to
be “Damaging”. PolyPhen-2 provides a position-specific,
independent count (PSIC) score difference, which was
assigned using the categories “probably damaging”
(2.00 or more), “possibly damaging” (1.40-1.90), “poten-
tially damaging” (1.20-1.50), “borderline” (1.00-1.20)
and “benign” (0.00-0.90).
Genotyping by pyrosequencing
One hundred and sixty-two healthy control samples
were Genotyped at nt 1021 on FH by pyrosequencing
(PSQ) using PyroMark Q96 (Qiagen), according to the
manufacture’s protocol. To enable single-strand prepar-
ation, the reverse primer was 5′-biotinylated. Reaction
volumes of 30 μl contained 5× GoTaq buffer, 1.5 units of
GoTaq Hot Start Polymerase (Promega), 1 μM of primers,
and 500 nM of dNTPs. PCR conditions were as follows:
95°C for 3 min; 45 cycles of 95°C for 30 s, 58°C for 30 s,
and 72°C for 30 s; and a final extension step at 72°C for
4 min. PCR primer sequences were: 5′-TTCTGTTTC
ACTTGCTAATGGTAGA-3′ (forward), and 5′-GGACC
TAGTCAAGTTTTAGCTCCA-3′ (reverse), respectively.
The sequencing primer sequence was 5′-AGTCTGAT-
GAAGATAGCAA-3′. We designed this assay so that if
c.1021G >A was an unreported SNP, it could detect all
nucleotide variations. Sequences to analyze were ATG/
NATATTC.
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